Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Withdrawn 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Conditions

Pancreatic Neoplasms 7Leukemia, Myeloid, Acute 6Neoplasms 4Precursor Cell Lymphoblastic Leukemia-Lymphoma 3Neoplasm Metastasis 3Sezary Syndrome 2Sarcoma, Myeloid 2Recurrence 2Mycosis Fungoides 2Lymphoma, Non-Hodgkin 2Lymphoma 2Lung Neoplasms 2Colonic Neoplasms 2Carcinoma, Hepatocellular 2Burkitt Lymphoma 2Waldenstrom Macroglobulinemia 1Stomach Neoplasms 1Small Cell Lung Carcinoma 1Sarcoma, Clear Cell 1Rectal Neoplasms 1Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 1Pancreatic Ductal Adenocarcinoma 1Pancreatic Cancer Metastatic 1Ovarian Neoplasms 1Myelodysplastic Syndromes 1Multiple Myeloma 1Lymphoma, T-Cell, Peripheral 1Lymphoma, T-Cell, Cutaneous 1Lymphoma, T-Cell 1Lymphoma, Mantle-Cell 1

Interventions

devimistat 1Bevacizumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
C04.588.274.476.411.307 × devimistat × Clear all
NCT05070104 2023-09-13

CPI-613 (Devimistat) in Combination With Modified FOLFIRINOX Plus Bevacizumab in Patients With Metastatic Colorectal Cancer

Cornerstone Pharmaceuticals

Phase 1 Withdrawn

C04.588.274.476.411.307

Data powered by HemOnc (CC BY 4.0) Colophon âš¡